BioAffinity Technologies Inc Dossier - Source-backed chat

BioAffinity Technologies Inc

BIAFNASDAQ

SectorHealth Care

IndustryHealth Care Equipment & Supplies

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.14Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $3.7M

Enterprise Value $2M

Shares Outstanding 600.7K diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

bioAffinity Technologies is demonstrating strong commercial momentum with its core noninvasive lung cancer diagnostic test, CyPath Lung. Unit sales surged 146% year-over-year in Q1 2026, and April 2026 unit sales grew nearly 300% year-over-year, reflecting rapid clinical adoption. However, the company remains in a high-burn development phase, having recently closed a dilutive $3.2 million public offering in June 2026 to bolster working capital. While the long-term market opportunity for early lung cancer detection is substantial, persistent net losses, going concern risks, and potential regulatory changes for laboratory-developed tests warrant a cautious Hold recommendation until the company establishes a clearer path to self-sustainability.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case involves persistent cash burn that quickly depletes the June 2026 capital raise, forcing further highly dilutive equity offerings. Commercial adoption of CyPath Lung slows due to intense competition or reimbursement hurdles. Additionally, tightening FDA regulations on laboratory-developed tests could impose costly clinical trial requirements, severely disrupting the company's business model and depressing the stock price.

Base CaseCentral scenario

The base case assumes bioAffinity successfully maintains its commercial momentum, achieving over 100% unit sales growth for CyPath Lung in FY 2026. The company leverages its newly raised $3.2 million to fund operations and advance its longitudinal clinical trial. Pulmonologist adoption continues to expand, and the company manages to maintain its Nasdaq listing, potentially utilizing the authorized reverse stock split if necessary. Revenue grows steadily, but profitability remains out of reach over the next 12-18 months.

Bull CaseUpside scenario

The bull case for bioAffinity Technologies centers on the rapid commercial adoption of CyPath Lung, which has shown high sensitivity (92%) and specificity (87%) in clinical trials. The strategic restructuring of PPLS to focus on high-margin diagnostics is expected to deliver $4 million in annual cost savings, accelerating the path to profitability. Furthermore, expansion into national markets and potential inclusion in the U.S. Federal Supply Schedule present significant revenue catalysts.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong commercial traction for CyPath Lung, with Q1 2026 unit sales up 146% and April 2026 unit sales up nearly 300% year-over-year.
High diagnostic accuracy of CyPath Lung, demonstrating 92% sensitivity, 87% specificity, and a 99% negative predictive value in clinical trials.
Strategic partnerships and clinical trials, including a large-scale longitudinal study with funding and support from the Murtha Cancer Center Research Program.

Key Investment Risks

Significant going concern risk and high cash burn rate, requiring frequent dilutive capital raises such as the $3.2 million offering in June 2026.
Regulatory uncertainty surrounding the FDA's oversight of laboratory-developed tests (LDTs), which could impact CyPath Lung's commercial model.
Nasdaq listing compliance risk, with the stock trading below the $1.00 minimum bid price, potentially requiring a highly dilutive reverse stock split.

Thesis Invalidation Triggers

Failure to sustain CyPath Lung unit sales growth above 100% in upcoming quarters.
Inability to secure additional non-dilutive funding or strategic partnerships before cash reserves fall below critical levels.
Adverse regulatory rulings from the FDA that restrict the marketing of CyPath Lung as a laboratory-developed test.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.